on Relief Therapeutics Holding SA (isin : CH1251125998)
Relief Therapeutics Announces 2024 Financial Results and Strategic Progress
Geneva-based Relief Therapeutics Holding SA has released its 2024 financial report, highlighting significant operational and strategic milestones. The biopharmaceutical company, known for its focus on rare and unmet medical needs, showcases a strengthened financial position and key advancements in its product pipeline.
Dr. Raghuram Selvaraju, chairman of the board, emphasized the company's achievements in his annual address to shareholders. The progress of treatments such as RLF-OD032 for phenylketonuria and RLF-TD011 for epidermolysis bullosa was particularly highlighted, with crucial clinical and regulatory events anticipated in 2025.
The annual report, now available online, includes detailed pipeline updates and financial disclosures.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holding SA news